Quantum Surgical has acquired NeuWave Medical, supporting its strategy to broaden access to robotic-assisted tumour ablation treatments for reducing cancer mortality.
The move brings together two medical device businesses with a shared focus on innovation for cancer patient outcomes.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Both companies will now operate as subsidiaries under Precision IO Group, a new parent company led by CEO Kurt Azarbarzin.
Quantum Surgical has developed the Epione robotic platform for early-stage tumour interventions. It enables physicians to perform percutaneous tumour ablations, inserting one or more needles through the skin to treat tumours.
NeuWave Medical provides microwave ablation technology for percutaneous procedures and reports usage in 70% of US cancer centres.
Quantum Surgical president and co-founder Bertin Nahum said: “At Quantum Surgical, we are committed to democratising procedural know-how through robotics and expanding high-quality cancer care for patients. Acquiring NeuWave Medical is a natural and strategic step in that mission.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData“Innovation is our north star, and we are thrilled to join forces with a passionate team of experts to drive innovation even further and shape the future of interventional oncology.”
NeuWave Medical president Leah Kissling said: “We’re proud to join the Quantum Surgical team and continue supporting physicians in their mission to treat cancer patients. We look forward to combining our capabilities with Quantum Surgical to drive innovation and help transform the future of cancer care.”
Precision IO Group is developing remote intervention projects using Epione tools, which facilitate global expert input for trajectory planning and results assessment.
Remote interventions will allow greater access to specialist care without travel, enabling real-time global collaboration among physicians for precise minimally invasive procedures.
Epione received the CE mark for chest, abdominal and musculoskeletal indications, along with US Food and Drug Administration (FDA) clearance for abdominal ablation. More than 1,400 patients have been treated with the technology in the US and Europe.
